Stocks Health care ELVN
NASDAQ · Health careEnliven Therapeutics, Inc. (ELVN)
It posted a net loss of $113.5M. In fiscal 2025 capital spending exceeded operating cash flow by $70.5M. At September 30, 2026 it held $151.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Enliven Therapeutics, Inc.
- Net worth
- Enliven Therapeutics, Inc. has a market value (market cap) of $3.8B at the latest share price, and shareholders' equity of $876.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $70.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Enliven Therapeutics, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Enliven Therapeutics, Inc. does
Enliven Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ELVN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$103.7M | -$1.83 | -$70.5M |
| 2024 | n/a | -$89M | -$1.89 | -$73.2M |
| 2023 | n/a | -$71.6M | -$2.01 | -$61.4M |
| 2022 | n/a | -$37.7M | -$12.05 | -$32.7M |
| 2021 | n/a | -$51.4M | -$2.37 | -$46.8M |
| 2020 | n/a | -$41.4M | -$3.53 | -$37.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Enliven Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 14, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026
- August 5, 2026
- June 24, 2026Activist stake changed SCHEDULE 13D/A
- June 22, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Enliven Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (73%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Kunkel Lori AnneDirector | Exercised options | 3,741 | $4.2K |
| October 30, 2026 | Kunkel Lori AnneDirector | Exercised options | 7,300 | $133.6K |
| October 19, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Exercised options | 5,000 | $12.4K |
| October 19, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER | Soldpre-planned (10b5-1) | 5,000 | $192.3K |
| October 19, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER | Exercised options | 6,018 | $89.4K |
| October 19, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 6,018 | $231.5K |
| October 1, 2026 | Garland J. ScottDirector | Exercised options | 13,000 | $201.1K |
| October 1, 2026 | Garland J. ScottDirector | Sold | 13,000 | $606.7K |
Who owns ELVN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | August 6, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 3 related filers | 9.5% | June 24, 2026 |
| Polar Capital Holdings Plc13G, passive with 2 related filers | 8.46% | June 22, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 7.7% | May 15, 2026 |
| BlackRock, Inc.13G, passive | 7.1% | October 27, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 5.4% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 211 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 10,025,017 | +3,195,771 |
| Orbimed Advisors LLC | 6,776,632 | -1,182,906 |
| Polar Capital Holdings Plc | 6,430,636 | +1,364,703 |
| BlackRock, Inc. | 4,359,704 | +674,997 |
| Vestal Point Capital, LP | 4,000,000 | +750,000 |
| Commodore Capital LP | 3,275,000 | 0 |
| Vanguard Capital Management LLC | 2,569,002 | +400,840 |
| Citadel Advisors LLC | 2,068,992 | +325,077 |
| Fairmount Funds Management LLC | 1,855,644 | 0 |
| Siren, L.L.C. | 1,774,411 | +1,028,185 |
| Bellevue Group AG | 1,490,000 | -830,867 |
| Geode Capital Management, LLC | 1,407,202 | +340,782 |
| First Light Asset Management, LLC | 1,360,750 | +1,158,883 |
| State Street Corp | 1,213,616 | +122,510 |
| Pictet Asset Management Holding SA | 1,161,784 | +232,240 |
| Adage Capital Partners GP, L.L.C. | 1,083,313 | new |
| Novo Holdings A/S | 1,000,000 | -280,000 |
| First Turn Management, LLC | 954,360 | +330,521 |
| Samlyn Capital, LLC | 912,637 | new |
| Baker Bros. Advisors LP | 905,191 | 0 |
Insiders
8 insiders reported holding 8,578,015 shares in total, about $439.2M at the last price.
| Holder | Shares |
|---|---|
| Orbimed Advisors LLC10% owner | 6,555,1026,555,102 held indirectly |
| Kintz SamuelPRESIDENT AND CEO, Director | 890,392890,392 held indirectly |
| Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER | 758,938740,188 held indirectly |
| Patel AnishCHIEF OPERATING OFFICER | 235,011215,011 held indirectly |
| Kunkel Lori AnneDirector | 52,925 |
| Hohl BenjaminCHIEF FINANCIAL OFFICER | 38,000 |
| Collins Helen LouiseCHIEF MEDICAL OFFICER | 25,000 |
| Heyman Richard A.Director | 22,64722,647 held indirectly |
Questions about ELVN
What does Enliven Therapeutics, Inc. do?
Enliven Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ELVN. Its shares trade on NASDAQ under the ticker ELVN.
What is Enliven Therapeutics, Inc.'s net worth?
Enliven Therapeutics, Inc. has a market value (market cap) of $3.8B at the latest share price, and shareholders' equity of $876.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Enliven Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $113.5M.
When did Enliven Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Enliven Therapeutics, Inc.'s next earnings report?
Enliven Therapeutics, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ELVN with
Follow ELVN
Get an email when Enliven Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Enliven Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.